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Introduction
============

Thymic stromal lymphopoietin (TSLP) is a novel IL-7--like cytokine, cloned from a murine thymic stromal cell line ([@bib1]). While mouse TSLP supports early B and T cell development, human TSLP (hTSLP) only activates CD11c^+^ dendritic cells (DCs), but not other antigen presenting cells, B, T, NK cells, neutrophils, nor mast cells ([@bib2], [@bib3]). This is in accordance with the coexpression of mRNA for the IL-7Rα chain and TSLPR by CD11c^+^ DCs but not other cell types ([@bib2]). Unlike most DC activators such as CD40-ligand and ligands for Toll-like receptors (LPS, CPG-DNA, poly I:C), hTSLP does not induce DCs to produce proinflammatory cytokines (IL-1, IL-6, TNF-α, and IL-12), but TH2-attracting chemokines TARC and MDC ([@bib3]). Interestingly, hTSLP-activated DCs prime CD4^+^ T helper cells to produce proallergic cytokines IL-4, IL-5, IL-13, and TNF-α, while down-regulating IL-10 and IFN-γ. hTSLP is highly expressed by epithelial cells of inflamed tonsils and keratinocytes of atopic dermatitis and its expression is associated with Langerhans cell migration and activation ([@bib3]). hTSLP represents the first epithelial cell--derived cytokine that directly triggers DC-mediated TH2 allergic inflammation.

Allergic inflammation is the result of a complex immunological cascade involving the production of TH2 cyto-kines IL-4, IL-5, and IL-13, which leads to eosinophilia and IgE-production by B cells ([@bib4], [@bib5]). The production of these proallergic TH2 cytokines was initially ascribed to CD4^+^ T cells ([@bib6], [@bib7]). There is now broader evidence that CD8^+^ T cells, once regarded solely as potent cytotoxic effectors in antiviral and antitumoral immunity, are also able to secrete TH2 cytokines ([@bib8]--[@bib10]). Substantial numbers of CD8^+^ T cells participate in allergic inflammation ([@bib11], [@bib12]). However, the functional properties of such CD8^+^ T cells as well as the pathways leading to their generation remain poorly understood.

In this study we demonstrate that human TSLP primes DCs to induce naive CD8^+^ T cell activation and differentiation into IL-5-- and IL-13--producing T cells. Additional CD40 ligand stimulation of TSLP-DCs induced the differentiation of CD8^+^ T cells into effectors that exhibit potent cytolytic activity and produce large amounts of IFN-γ, in addition to IL-5 and IL-13, two types of cyto-kines that were considered to be mutually exclusive ([@bib13]). Our data suggest that TSLP-activated DCs play an important role in inducing both CD4^+^ and CD8^+^ T cell--mediated allergic inflammation.

Materials and Methods
=====================

DC Purification and Culture.
----------------------------

CD11c^+^ DCs were purified from buffy coats of HLA-A2--positive volunteer blood donors after separation of PBMCs by Ficoll-Hypaque centrifugation (Amersham Biosciences) and immunomagnetic depletion using mouse anti-CD3 (OKT3), anti-CD14 (RPA-M1), anti-CD19 (Leu-12), anti-CD56 (Leu-19), and anti-glycophorin-A (10F7MN) followed by magnetic beads coated with goat anti--mouse IgG (Dynabeads M-450; Dynal). Depleted cells were further stained with PE-Cy5--conjugated anti-CD4 (Caltag), PE-conjugated anti-CD11c and FITC-conjugated anti-CD3, CD14, CD16, and CD20 (all Becton Dickinson). FITC^−^CD11c^+^ DCs were isolated with a Vantage FACsorter™ (Becton Dickinson) to reach a purity \>99% .

CD11c^+^ DCs were cultured immediately after sorting in RPMI containing 10% FCS, 1% pyruvate, 1% HEPES, and penicillin-streptomycin. Cells were seeded at 0.5 × 10^6^/ml in flat-bottomed 96-well plates in the presence of medium alone, TSLP (15 ng/ml), CD40L-transfected L fibroblasts (2.5 × 10^4^/well), or a combination of TSLP and CD40L-transfected L fibroblasts. DCs were harvested after 24 h of culture and stained with FITC-labeled anti-CD80 and anti-CD86 (Becton Dickinson) to assess their state of maturation.

Isolation of Naive CD8^+^ T Lymphocytes from Adult Blood.
---------------------------------------------------------

Naive CD8^+^ T cells were enriched from PBMCs of HLA-A2--negative healthy donors by immunomagnetic depletion using a cocktail of mouse anti-CD4, anti-CD14, anti-CD16, anti-CD19, anti-HLA-DR, and anti-CD45RO mAb, followed by magnetic beads coated with goat anti--mouse IgG. These cells were stained with PE-Cy5--conjugated anti-CD45RA, PE-conjugated anti-CD27 (both BD Biosciences), and a cocktail of FITC-conjugated anti-CD4, anti-γδTCR, anti-CD14, anti-CD16, and anti-CD20 mAbs (Becton Dickinson). CD27^+^CD45RA^+^lineage^−^ cells were isolated by fluorescence activated cell sorting and were \>98% CD8^+^ T cells. CD8^+^CD27^+^CD45RA^+^ have been previously described as naive CD8^+^ T cells.

DC/CD8 T Cell Cocultures.
-------------------------

CD11c^+^ DCs were collected after 24 h of culture under different conditions, washed twice to remove any residual cytokine, and cultured with 5 × 10^4^ freshly isolated naive CD8^+^ T cells in round-bottomed 96-well plates at a ratio of 1:5 DC:T cell. After 6 d, cultures were harvested and numbers of viable cells determined by trypan blue exclusion.

Analysis of Cytokine Production.
--------------------------------

To test their capacity to secrete cytokines, harvested CD8^+^ T cells (10^6^/ml) were restimulated with plate-bound anti-CD3 mAb (10 μg/ml) plus 1 μg/ml soluble anti-CD28 mAb for 24 h. IFN-γ, TNF-α, IL-4, IL-5, IL-13, and IL-10 in the culture supernatants were measured by Quantikine ELISA kits (R&D Systems).

Cytotoxicity Assay and Intracellular Perforin Expression.
---------------------------------------------------------

Harvested CD8^+^ T cells were tested for the capacity to lyse ^51^Cr-labeled HLA-A2--positive EBV-B lymphoblastoid cell line JY. The HLA-A2--negative EBV-LCL RSB cell line (DNAX) was used as negative control target. The assay was performed by incubating 2,500 ^51^Cr-labeled target cells per well with indicated numbers of effectors at 37°C for 5 h before collecting the supernatants and measuring ^51^Cr release with a gamma counter. We used Triton X to determine the maximum lysis, and target cells alone to determine the spontaneous lysis. The percentage lysis was calculated as follows: (spontaneous cpm − experimental cpm)/spontaneous cpm. For quantification of perforin expression by CD8 T cells, harvested cells were stained with PE-labeled anti-CD8, fixed with 2% formaldehyde (Sigma-Aldrich), and permeabilized with PBS supplemented with 2% FCS, 0.1% NaN3, and 0.5% saponin (Sigma-Aldrich). Cells were then stained with FITC-labeled anti-perforin mAb (for 20 min) and analyzed on a FACScan™ flow cytometer.

Results
=======

TSLP-DCs Induce Strong CD8^+^ T Cell Expansion.
-----------------------------------------------

The capacity of DCs cultured with human TSLP (TSLP-DC) to activate and differentiate naive CD8^+^ T cells was determined in comparison to DCs cultured either with medium alone, CD40L (CD40L-DC), or with a combination of TSLP and CD40L (CD40L+TSLP-DC). Whereas DCs cultured with medium alone did not induce significant CD8^+^ T cell expansion, CD40L-DCs induced a 1.4 to 2.8-fold expansion of CD8^+^ T cells after 6 d of coculture ([Fig. 1](#fig1){ref-type="fig"} A). TSLP-DCs induced a 2.8 to 5.6-fold increase in CD8^+^ T cell number, which was 2 times more than that induced by CD40L-DCs ([Fig. 1](#fig1){ref-type="fig"} A). CD40L and TSLP had a strong synergistic effect in activating DCs, as shown by the very high levels of CD80 and CD86 expression ([Fig. 1](#fig1){ref-type="fig"} B), and the ability to induce the strongest CD8^+^ T cell expansion (4.5 to 8.2-fold). Thus, TSLP, either alone or in combination with CD40L, represents a very potent DC activation factor with a marked capacity to induce DC-mediated activation and expansion of naive CD8^+^ T cells.

###### 

CD11c^+^ DCs activated by TSLP alone or in combination with CD40L induce a strongly expansion of naive CD8^+^ T cells. (A) Naive CD8^+^ T cells were cultured for 6 d with CD11c^+^ DCs activated for 24 h with medium, CD40L, TSLP, or TSLP + CD40. TSLP-DCs induced stronger expansion of naive CD8^+^ T cells than CD40-L-DCs. The combination of TSLP and CD40L showed an additive effect on the capacity of activated DCs to induce CD8^+^ T cell expansion. Data represent five independent experiments; horizontal bars represent the median value. (B) Surface expression of CD80 and CD86 by medium-DCs, CD40L-DCs, TSLP-DCs, and TSLP+CD40L-DCs. TSLP-DCs showed significantly higher levels of CD80 than CD40L-DCs, TSLP+CD40L-DCs showed the highest levels of both CD80 and CD86. Filled histograms represent staining of costimulatory molecules CD80 and CD86; open histograms represent the isotype control. Numbers indicate the mean fluorescence intensity.
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TSLP-DCs Prime CD8^+^ T Cells to Produce Large Amounts of IL-5 and IL-13.
-------------------------------------------------------------------------

To determine the capacity of TSLP-DCs to polarize naive CD8^+^ T cells into cytokine-producing cells, DC-primed CD8^+^ T cells were restimulated for 24 h with anti-CD3 and anti-CD28 and cytokine production was measured in the culture supernatant by ELISA ([Fig. 2](#fig2){ref-type="fig"}) . CD8^+^ T cells primed with medium-DCs produced low levels of IFN-γ and TNF-α, and did not produce detectable amounts of IL-4, IL-5, or IL-10. CD8^+^ T cells primed with CD40L-DCs produced large amounts of IFN-γ and TNF-α, low amounts of IL-5 and undetectable amounts of IL-13, IL-4, or IL-10. Interestingly, CD8^+^ T cells primed by TSLP-DCs produced large amounts of IL-5 (up to 350 pg/ml) and IL-13 (up to 170 pg/ml), and moderate amounts of IFN-γ and TNF-α, but did not produce detectable amounts of IL-4 and IL-10. DCs activated by TSLP together with CD40L primed CD8^+^ T cells to produce the highest levels of IL-5, IL-13, TNF-α, and IFN-γ, but undetectable amounts of IL-4 and IL-10.

![TSLP-activated DCs induce IL-5 and IL-13--producing CD8^+^ T cells. Cytokine production by naive CD8^+^ T cells primed for 6 d with medium-DCs, CD40L-DCs, TSLP-DCs, or TSLP+CD40L-DCs. Harvested CD8^+^ T cells were restimulated for 24 h with anti-CD3 and anti-CD28 and IFN-γ, TNF-α, IL-4, IL-5, IL-10, and IL-13 were measured in the culture supernatant by ELISA. TSLP-DCs and TSLP+CD40L-DCs both induced IL-5 and IL-13 producing CD8^+^ T cells. However, in contrast to TSLP-DCs, TSLP+CD40L-DCs primed CD8^+^ T effector cells to produce high levels of IFN-γ. Data represent one of three independent experiments.](20030240f2){#fig2}

TSLP-DC Activated in the Presence of CD40L Induce Highly Cytotoxic CD8^+^ T Cells and Secrete IL-5, IL-13, and IFN-γ.
---------------------------------------------------------------------------------------------------------------------

Next, we asked whether these polarized effector CD8^+^ T cells had characteristics of cytotoxic T cells and could kill allogeneic targets ([Fig. 3](#fig3){ref-type="fig"} A). DCs cultured for 24h in medium alone did not induce cytotoxic CD8^+^ T cell activity (cytolytic activity was not significantly different from cytolytic activity against autologous targets). Low levels of cytotoxic activity were detected in both CD8^+^ T cells primed with CD40L-DC or TSLP-DCs (cytolytic activity detectable at the lowest ratio of 15 effector to 1 target cell). In contrast, CD40L-TSLP-DCs induced very potent of CD8^+^ cytotoxic T cells, detectable at ratios as low as 1 effector to 1 target ([Fig. 3](#fig3){ref-type="fig"} A). The cytotoxic activity correlated with the intracellular perforin expression ([Fig. 3](#fig3){ref-type="fig"} B).

###### 

CD40L-TSLP-DCs induced the generation of CD8^+^ cytotoxic effector T cells. (A) Naive CD8^+^ T cells were primed for 6 d with medium-DCs (triangles), CD40L-DCs (diamonds), TSLP-DCs (circles), or TSLP+CD40L-DCs (squares), collected and tested for their ability to lyse allogeneic HLA-A2--positive target cells. Specific lysis of autologous HLA-A2--negative target cells remained below 15%. Whereas both TSLP-DCs and CD40L-DCs induced CD8^+^ T cells with poor cytolytic activity, TSLP+CD40L-DCs induced CD8^+^ T cells with potent cytolytic activity. Data represent one of three independent experiments. (B) Two color staining for intracellular perforin and surface CD8 of T cells primed with medium-DCs, CD40-L-DCs, TSLP-DCs, or TSLP+CD40-L-DCs for 6 d.

![](20030240f3a)

![](20030240f3b)

Discussion
==========

In this study, we report that DCs activated by TSLP have a marked ability to expand naive CD8^+^ T cells and induce their differentiation into IL-5 and IL-13 secreting CD8^+^ T cells. Furthermore, we show that the addition of CD40L to the TSLP-mediated DC activation induced CD8^+^ T cell differentiation into potent cytolytic effectors secreting high levels of IFN-γ, while retaining their ability to produce high levels of IL-5 and IL-13.

The importance of CD8^+^ T cells in the pathogenesis and exacerbation of allergic diseases has been recently highlighted by the identification of allergen-specific CD8^+^ T cells ([@bib14]). In addition, large numbers of CD8^+^ T cells secreting IL-5 and IL-13 have been observed in the inflammatory infiltrate of allergic asthma ([@bib15]) and atopic dermatitis ([@bib12]) as well as in the blood of patients with drug allergies ([@bib16]). CD8^+^ T cell--derived IL-5 and IL-13 were shown to exert their proallergic functions by inducing eosinophilia and increased IgE production, both in-vitro and in-vivo ([@bib12], [@bib17]). Interestingly, IL-10, a cytokine also produced by Th2 clones, was shown to be decreased in allergic diseases ([@bib14], [@bib18]), and can suppress allergic inflammation ([@bib19], [@bib20]). In our study, CD8^+^ T cells induced by TSLP-activated DCs produced high levels of IL-5 and IL-13, but low levels of IL-10, thus exhibiting a typical proallergic cytokine profile. This parallels our data on CD4^+^ T cells, which can be instructed to produce high levels of proallergic cytokines but low levels of IL-10, when cultured with TSLP-activated DCs ([@bib3]).

Allergic inflammation typically develops in two phases with a switch from the initial type 2 cytokine profile in acute lesions to increasing levels of IFN-γ and high numbers of cytolytic effectors in chronic lesions, while proallergic type 2 cytokines still remain at high levels ([@bib21]--[@bib23]). In atopic dermatitis, both the increased IFN-γ production as well as the presence of high numbers of cytotoxic T cells represent key pathogenic factors leading to epidermal injury and the formation of the eczematous lesion ([@bib24], [@bib25]). In allergic asthma, CD8^+^ T cell--derived IFN-γ has been linked to bronchial hyperresponsiveness ([@bib26], [@bib27]) and the number of lesional cytotoxic CD8^+^ T cells have been associated with the severity of the disease ([@bib28]). Our data suggest that TSLP may represent the initial trigger of allergic inflammation, by instructing DCs to induce IL-5 and IL-13 production by CD8^+^ T cells. In a second step, CD40L triggering of TSLP-activated DCs could induce IFN-γ production and high cytotoxicity by CD8^+^ T cells, which would have characteristics of pathogenic T cells of the late phases of allergy. These IL-5, IL-13, and IFN-γ--producing cytolytic effectors might act to amplify and sustain the proallergic response, and to cause tissue damage. In this two-step process, an important question is the source of CD40L, in vivo. It is generally accepted that CD40L stimulation essentially comes from activated CD4^+^ T cells within secondary lymphoid organs, during the DC--T cell cross-talk ([@bib29]). However, a number of CD40L-expressing cells are recruited to the site of allergic inflammation and could deliver a CD40 trigger to the TSLP-activated DCs, in situ. These include Ag-specific T helper cells, but also eosinophils and basophils, which express significant levels of CD40L ([@bib30]).

Our study provides further evidence that human TSLP might represent a key early mediator of allergic inflammation. The central role of TSLP, which acts upstream of both CD4^+^ and CD8^+^ proallergic T cell responses, should encourage clinical studies with specific TSLP inhibitors in allergic diseases.
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